文献速递产科母胎医学

妊娠期二甲双胍使用与儿童神经发育结局:系统综述与荟萃分析

Metformin in pregnancy and childhood neurodevelopmental outcomes: a systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2024-03-07

该系统综述与荟萃分析检索MEDLINE、Embase和Web of Science(核心合集)至2023年7月1日,纳入7项研究、共14,042名儿童(暴露组7,641名,随访至14岁)。妊娠期二甲双胍使用与婴儿期神经发育迟缓(相对风险1.09,95%CI 0.54-2.17;3项研究;9,668名儿童)及3至5岁(相对风险0.90,95%CI 0.56-1.45;2项研究;6,118名儿童)均无关联;与未暴露同龄儿相比,运动评分(均数差0.30,95%CI -1.15至1.74;3项研究;714名儿童)和认知评分(均数差-0.45,95%CI -1.45至0.55;4项研究;734名儿童)均无显著差异。作者结论认为宫内暴露于二甲双胍似乎与儿童至14岁的不良神经发育结局无关。

要点

  • 妊娠期二甲双胍使用与婴儿期神经发育迟缓无关联(相对风险1.09,95%CI 0.54-2.17)。
  • 妊娠期二甲双胍使用与3至5岁神经发育迟缓无关联(相对风险0.90,95%CI 0.56-1.45)。
  • 与未暴露同龄儿相比,运动评分和认知评分均无显著差异。

核心结论

  • 宫内暴露于二甲双胍似乎与儿童至14岁的不良神经发育结局无关,这些发现为考虑妊娠期使用二甲双胍的临床医生和孕妇提供了 reassurance。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase和Web of Science(核心合集)自建库至2023年7月1日。
  • 纳入标准为任何孕期阶段因任何指征接受二甲双胍治疗且子代有神经发育数据的女性研究,排除无对照组的研究。
  • 纳入随机对照试验、病例对照、队列和横断面研究,共7项研究符合纳入标准,合并队列14,042名儿童,其中暴露组7,641名,随访至14岁。
  • 由2名评价者独立筛选文献并提取数据,非随机研究采用改良版纽卡斯尔-渥太华量表评估偏倚风险,随机试验采用偏倚风险2工具。

主要发现

  • 妊娠期二甲双胍使用与婴儿期神经发育迟缓无关联(相对风险1.09,95%CI 0.54-2.17;3项研究;9,668名儿童)。
  • 妊娠期二甲双胍使用与3至5岁神经发育迟缓无关联(相对风险0.90,95%CI 0.56-1.45;2项研究;6,118名儿童)。
  • 与未暴露同龄儿相比,妊娠期二甲双胍使用与运动评分改变无关联(均数差0.30,95%CI -1.15至1.74;3项研究;714名儿童)。
  • 与未暴露同龄儿相比,妊娠期二甲双胍使用与认知评分改变无关联(均数差-0.45,95%CI -1.45至0.55;4项研究;734名儿童)。
  • 纳入研究质量高,被判定为低偏倚风险。

关键数值与推荐

  • 妊娠期二甲双胍使用与婴儿期神经发育迟缓:相对风险1.09(95%CI 0.54-2.17;3项研究;9,668名儿童)。
  • 妊娠期二甲双胍使用与3至5岁神经发育迟缓:相对风险0.90(95%CI 0.56-1.45;2项研究;6,118名儿童)。
  • 妊娠期二甲双胍使用与运动评分:均数差0.30(95%CI -1.15至1.74;3项研究;714名儿童)。
  • 妊娠期二甲双胍使用与认知评分:均数差-0.45(95%CI -1.45至0.55;4项研究;734名儿童)。

临床怎么用

  • 作者结论认为宫内暴露于二甲双胍似乎与儿童至14岁的不良神经发育结局无关,这些发现为考虑妊娠期使用二甲双胍的临床医生和孕妇提供了 reassurance。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to examine the impact of maternal metformin use during pregnancy on offspring neurodevelopmental outcomes. DATA SOURCES: MEDLINE, Embase, and Web of Science (Core Collection) were searched from inception until July 1, 2023. STUDY ELIGIBILITY CRITERIA: Studies of women who received treatment with metformin at any stage of pregnancy for any indication with neurodevelopmental data available for their offspring were included. Studies without a control group were excluded. Randomized controlled trials, case-control, cohort, and cross-sectional studies were included in the review. METHODS: Studies were screened for inclusion and data were extracted independently by 2 reviewers. Risk of bias was assessed using a modified version of the Newcastle-Ottawa Scale for nonrandomized studies, and the Risk of Bias 2 tool for randomized trials. RESULTS: A total of 7 studies met the inclusion criteria, including a combined cohort of 14,042 children with 7641 children who were exposed and followed for up to 14 years of age. Metformin use during pregnancy was not associated with neurodevelopmental delay in infancy (relative risk, 1.09; 95% confidence interval, 0.54-2.17; 3 studies; 9668 children) or at ages 3 to 5 years (relative risk, 0.90; 95% confidence interval, 0.56-1.45; 2 studies; 6118 children). When compared with unexposed peers, metformin use during pregnancy was not associated with altered motor scores (mean difference, 0.30; 95% confidence interval, -1.15 to 1.74; 3 studies; 714 children) or cognitive scores (mean difference, -0.45; 95% confidence interval, -1.45 to 0.55; 4 studies; 734 children). Studies that were included were of high quality and deemed to be at low risk of bias. CONCLUSION: In utero exposure to metformin does not seem to be associated with adverse neurodevelopmental outcomes in children up to the age of 14 years. These findings provide reassurance to clinicians and pregnant women considering metformin use during pregnancy.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gordon HG, Atkinson JA, Tong S, et al. Metformin in pregnancy and childhood neurodevelopmental outcomes: a systematic review and meta-analysis. Am J Obstet Gynecol. 2024. PMID: 38460832. doi:10.1016/j.ajog.2024.02.316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。